Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Janet R Vos"'
Autor:
Ane J. Schei-Andersen, Bart van Oirschot, Meggie M.C.M. Drissen, Jolanda Schieving, Janneke H.M. Schuurs-Hoeijmakers, Janet R. Vos, Claire M. Barton, Nicoline Hoogerbrugge
Publikováno v:
International Dental Journal, Vol 74, Iss 6, Pp 1424-1431 (2024)
Aims: Patients with PTEN hamartoma tumour syndrome (PHTS) have an increased risk of developing cancer due to a pathogenic germline variant in the PTEN tumour suppressor gene. Early recognition of PHTS facilitates initiation of cancer surveillance whi
Externí odkaz:
https://doaj.org/article/44d12c677a194939a3a37bde7d23ca3b
Publikováno v:
Gynecologic Oncology Reports, Vol 38, Iss , Pp 100825- (2021)
Externí odkaz:
https://doaj.org/article/244604906aaf4802a9832a1a7d01fdeb
Autor:
Peggy Manders, Janet R. Vos, Richarda M. de Voer, Liselot P. van Hest, Rolf Sijmons, Chantal V. Hoge, Fokke G. Terpstra, Manon C. Spaander, Wilma E. Mesker, Evelien Dekker, Nicoline Hoogerbrugge, on behalf of the Biobank Hereditary Colorectal Cancer
Publikováno v:
Open Journal of Bioresources, Vol 6 (2019)
Each year approximately 15,000 patients are diagnosed with colorectal cancer (CRC) in the Netherlands, of whom 5–10% are associated with a hereditary syndrome. To enable future research into hereditary CRC, we established a collaborative biobank fo
Externí odkaz:
https://doaj.org/article/91efb0d449544450a9dbff556c8309b6
Autor:
Alma Hoxhaj, Meggie M.C.M. Drissen, Janet R. Vos, Peter Bult, Ritse M. Mann, Nicoline Hoogerbrugge
Publikováno v:
Cancer, 128, 2883-2891
Cancer, 128, 15, pp. 2883-2891
Cancer, 128, 15, pp. 2883-2891
Contains fulltext : 287842.pdf (Publisher’s version ) (Open Access) Background Women with PTEN Hamartoma Tumor Syndrome (PHTS) are offered breast cancer (BC) surveillance because of an increased BC lifetime risk. Surveillance guidelines are, howeve
Autor:
Janet R. Vos, Tjalling Bosse, Margreet G. E. M. Ausems, Majke H.D. van Bommel, Marjolijn J. L. Ligtenberg, Marian J.E. Mourits, Nicoline Hoogerbrugge, Vera M. Witjes, Joanne A. de Hullu
Publikováno v:
Gynecologic Oncology, 164, 1, pp. 221-230
Gynecologic Oncology, 164, 221-230
Gynecologic Oncology, 164, 221-230
Contains fulltext : 244552.pdf (Publisher’s version ) (Open Access) BACKGROUND: Histology restricted genetic predisposition testing of ovarian carcinoma patients is a topic of debate as the prevalence of BRCA1/2 pathogenic variants (PVs) in various
Autor:
Geertruida H. de Bock, Jan C. Oosterwijk, Liesbeth Jansen, Annemarie H. van der Hout, Richard M. Brohet, Hans F. Vasen, Encarna B. Gómez-Garcia, Hanne E.J. Meijers-Heijboer, Theo A.M. van Os, Margreet G.E.M. Ausems, Arjen R. Mensenkamp, Christi J. van Asperen, Margriet Collée, Flora E. van Leeuwen, Matti A. Rookus, Marian J.E. Mourits, Dorina M. van der Kolk, Natalia Teixeira, Janet R. Vos
Supplementary Table 1. Clinical characteristics of BRCA1/2 carriers including index cases in the Northern Netherlands (study population) and in the rest of the Netherlands (reference population). Supplementary Table 2. Overview of number of carriers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5038904ce7d8f9b24a5ec82049ab87b
https://doi.org/10.1158/1055-9965.22435510.v1
https://doi.org/10.1158/1055-9965.22435510.v1
Autor:
Geertruida H. de Bock, Jan C. Oosterwijk, Liesbeth Jansen, Annemarie H. van der Hout, Richard M. Brohet, Hans F. Vasen, Encarna B. Gómez-Garcia, Hanne E.J. Meijers-Heijboer, Theo A.M. van Os, Margreet G.E.M. Ausems, Arjen R. Mensenkamp, Christi J. van Asperen, Margriet Collée, Flora E. van Leeuwen, Matti A. Rookus, Marian J.E. Mourits, Dorina M. van der Kolk, Natalia Teixeira, Janet R. Vos
Background: We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation carriers (BRCA2 carriers) older than 60 in the Northern Netherlands, and to analyze whether these could be explained by mutation spectrum or populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee2fb7a1642cf211acd7fd8abc807b8
https://doi.org/10.1158/1055-9965.c.6514963
https://doi.org/10.1158/1055-9965.c.6514963
Autor:
Geertruida H. de Bock, Marian J. Mourits, Margreet G.E.M. Ausems, Agnes Jager, Arjen R. Mensenkamp, Encarna B. Gómez Garcia, Christi J. van Asperen, Annemarie H. van der Hout, Muriel A. Adank, Matti A. Rookus, Cora M. Aalfs, Jan C. Oosterwijk, Janet R. Vos
Personal and family history at initial referral of the family and personal DNA test.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b57ced148c5f39552315aee2f4cde7
https://doi.org/10.1158/1055-9965.22437883.v1
https://doi.org/10.1158/1055-9965.22437883.v1
Autor:
Lisa Elze, Rachel S van der Post, Janet R Vos, Arjen R Mensenkamp, Mirjam S C de Hullu, Iris D Nagtegaal, Nicoline Hoogerbrugge, Richarda M de Voer, Marjolijn J L Ligtenberg
Publikováno v:
Journal of the National Cancer Institute, 115, 7, pp. 853-860
Background Individuals with Lynch syndrome are at increased hereditary risk of colorectal and endometrial carcinomas with microsatellite instability (MSI-H) and mismatch repair-deficiency (dMMR), which make these tumors vulnerable to therapy with imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228cc918621fad1c21ea38f698649e8e
https://doi.org/10.1093/jnci/djad063
https://doi.org/10.1093/jnci/djad063
Autor:
Vera M. Witjes, Marjolijn J.L. Ligtenberg, Janet R. Vos, Jozé C.C. Braspenning, Margreet G.E.M. Ausems, Marian J.E. Mourits, Joanne A. de Hullu, Eddy M.M. Adang, Nicoline Hoogerbrugge
Publikováno v:
Gynecologic Oncology, 174, pp. 121-128
Gynecologic Oncology, 174, 121-128
Gynecologic Oncology, 174, 121-128
Objective: Genetic testing in epithelial ovarian cancer (OC) is essential to identify a hereditary cause like a germline BRCA1/2 pathogenic variant (PV). An efficient strategy for genetic testing in OC is highly desired. We evaluated costs and effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e688aecb3f810e9269ae2ae895e4067c